This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Intrathecal DepoCyte and Lineage-targeted Minimal Residual Disease-oriented Therapy of Acute Lymphoblastic Leukemia

This study has been completed.
Information provided by (Responsible Party):
DR RENATO BASSAN, Northern Italy Leukemia Group Identifier:
First received: November 19, 2008
Last updated: October 21, 2014
Last verified: October 2014

The aim of this clinical study in adult ALL is to compare by risk category (1) the feasibility of two different CNS prophylaxis regimens and (2) the overall disease-free survival in relation to the achievement of an early MRD negative status and following consolidation with lineage-targeted methotrexate infusions and other disease-specific therapeutic elements, with or without the application of allogeneic or autologous SCT depending on risk class and MRD study results.

In this multicentric prospective pilot randomized phase II trial on CNS prophylaxis, all patients receive induction/consolidation therapy incorporating lineage-targeted high-dose methotrexate plus other drugs (with additional imatinib in Ph/BCR-ABL+ ALL), for the achievement of an early negative MRD status. The MRD study supports a risk/MRD-oriented final consolidation phase.

Condition Intervention Phase
Acute Lymphoblastic Leukemia Drug: liposome-encapsulated cytarabine (DepoCyte) Drug: Triple intrathecal therapy (TIT) Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Study on CNS Prophylaxis With Liposome-Encapsulated Cytarabine in Association With a Lineage-Targeted and MRD-Oriented Postremission Strategy in Adult ALL

Resource links provided by NLM:

Further study details as provided by DR RENATO BASSAN, Northern Italy Leukemia Group:

Primary Outcome Measures:
  • Comparative analysis of feasibility/toxicity of IT DepoCyte vs. TIT [ Time Frame: weeks 5, 11, 17 and 23 ]

Secondary Outcome Measures:
  • Comparative analysis of isolated and combined CNS recurrence following TIT vs DepoCyte prophylaxis [ Time Frame: During study follow-up ]
  • Complete remission (CR) [ Time Frame: After study chemotherapy cycles 1 and 2 ]
  • Bone marrow MRD negativity rates [ Time Frame: Four time-points at weeks 4-22 ]
  • Lenght of remission [ Time Frame: Study follow-up ]
  • Overall survival [ Time Frame: Study follow-up ]

Enrollment: 145
Study Start Date: January 2008
Study Completion Date: October 2013
Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Intrathecal DepoCyte
I.t. DepoCyte 50 mg admninistered x6-8 (depending on immunophenotypic disease subset) during induction/consolidation/eraly maintenance phases
Drug: liposome-encapsulated cytarabine (DepoCyte)
DepoCyte 50 mg injected intrathecally x6-8 (6: B-lineage, 8: T-lineage) during induction/consolidation phases
Other Names:
  • DepoCyte
  • DepoCyt
Active Comparator: Triple intrathecal therapy (TIT)
Methotrexate 12,5 mg + Cytarabine 50 mg + Prednisolone 40 mg injected intrathecally x12 during indiction/consolidation phases
Drug: Triple intrathecal therapy (TIT)
Methotrexate 12,5 mg + Cytarabine 50 mg + Prednisolone 40 mg. injected intrathecally x12 during induction/consolidation therapy
Other Names:
  • Methotrexate
  • Cytosine arabinoside
  • Cytosar

  Show Detailed Description


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18-65 years.
  • Diagnosis of untreated ALL with B-/T-precursor phenotype or B-cell lymphoblastic lymphoma (B-LL), either de novo or secondary to chemo-radiotherapy for other cancer.
  • Full cytological, cytochemical, cytogenetic and immunobiological disease characterization by revised FAB, EGIL and WHO criteria.
  • Bone marrow and peripheral blood sampling (ALL) or biopsy specimen (LL) for MRD study.
  • ECOG performance status 0-2 or reversible ECOG 3 score following intensive care of complications.
  • Signed informed consent.

Exclusion Criteria:

  • Diagnosis of B-ALL (FAB L3 ALL/Burkitt's leukemia or lymphoma) and T-LL (T-cell lymphoblastic lymphoma).
  • Down's syndrome.
  • Pre-existing, uncontrolled pathology such as cardiac disease (congestive/ischemic, acute myocardial infarction within the past 3 months, untreatable arrythmias, NYHA classes III and IV), severe liver disease with serum bilirubin >3 mg/dL and/or ALT >3 x upper normal limit (unless attributable to ALL/LL), kidney function impairment with serum creatinine >2 mg/dL (unless attributable to ALL/LL), and severe neurological or psychiatric disorder that impairs the patient's ability to understand and sign the informed consent, or to cope with the intended treatment plan.
  • Known HIV positive serology.
  • Other active hematological or non-hematological cancer with life expectancy <1 year.
  • Pregnancy (fertile women will be advised not to become pregnant while on treatment; and male patients to adopt contraceptive methods), unless therapeutic aborption/early discharge is carried out.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00795756

USC Ematologia, Ospedale Civile
Alessandria, (al), Italy
USC Ematologia, Ospedali Riuniti
Bergamo, (bg), Italy, 24128
Divisione di Ematologia - Spedali Civili
Brescia, (bs), Italy
Divisione di Ematologia e TMO, Ospedale San Maurizio
Bolzano, (bz), Italy
Ematologia e centro TMO - Ospedale Armando Businco
Cagliari, (ca), Italy
S.C. Ematologia - Azienda Ospedaliera S. Croce e Carle
Cuneo, (cn), Italy
Ematologia e centro TMO, Istituti Ospedalieri
Cremona, (cr), Italy
Ematologia - AOU Careggi
Firenze, (fi), Italy
Ematologia e centro TMO - IRCSS Mangiagalli Regina Elena
Milano, (mi), Italy
Ematologia e centro TMO, Ospedale San Raffaele
Milano, (mi), Italy
Ematologia e centro TMO, Ospedale San Gerardo
Monza, (mi), Italy
Oncoematologia e TMO - Dipartimento Oncologico La Maddalena
Palermo, (pa), Italy
Ematologia 2 - Ospedale San Giovanni Battista
Torino, (to), Italy
Medicina Interna I - Ospedale di Circolo
Varese, (va), Italy
Onco-Ematologia - Ospedale Civile
Noale, (ve), Italy
Ematologia - Ospedale San Bortolo
Vicenza, (vi), Italy
Sponsors and Collaborators
Northern Italy Leukemia Group
Study Chair: Renato Bassan, MD USC Ematologia, Ospedali Riuniti, Bergamo (Italy)
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: DR RENATO BASSAN, Medical Doctor, Northern Italy Leukemia Group Identifier: NCT00795756     History of Changes
Other Study ID Numbers: NILG-ALL 10/07
Study First Received: November 19, 2008
Last Updated: October 21, 2014

Keywords provided by DR RENATO BASSAN, Northern Italy Leukemia Group:
Central nervous system prophylaxis
Minimal residual disease

Additional relevant MeSH terms:
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Neoplasm, Residual
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Neoplastic Processes
Pathologic Processes
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunosuppressive Agents
Immunologic Factors
Antirheumatic Agents
Nucleic Acid Synthesis Inhibitors
Antiviral Agents processed this record on August 18, 2017